Absci (ABSI) announced the appointment of seasoned R&D executive Professor Sir Menelas “Mene” Pangalos to its Board of Directors and as co-chair of Absci’s Scientific Advisory Board. Sir Pangalos was the Executive Vice President of BioPharmaceuticals R&D at AstraZeneca (AZN). He joins Absci as the company scales its AI-enabled portfolio of partnered and wholly-owned assets.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABSI:
- Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
- Absci price target raised to $7 from $4 at H.C. Wainwright
- Absci to present preclinical data for ABS-101
- Absci to Participate in the 26th Annual Needham Growth Conference
- Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference